갑상선질환 환자의 방사성요오드 치료시 방사선 안전관리
Radiation Safety in the Treatment of Patients with Thyroid Disease by 131I
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Radioactive iodine (131I) therapy is a well established treatment modality for patient with hyperthyroidism and differentiated thyroid cancer after total thyroidectomy. Patients may sometimes need to be hospitalized to reduce radiation exposure of other people and relatives from radioactive patients receiving 131I therapy. This review was prepared to present suggestions and recommendations to health providers with reasoned instructions on radiation safety for patients, their families, caregivers, and the public after 131I therapy. The recommendations should help to ensure compliance and reduce the potential for harmful radiation exposure to others, and also to recognize that required actions may differ when attaining compliance with existing local regulations of other jurisdictions. Most of reported suggestions and recommendations are based on data derived from relevant measurements of radiation exposure, 131I clearance and excretion, and reports of the impact of precautions in limiting radiation exposure. We have quoted many descriptions from American Thyroid Association Guidelines in this review, which was published recently and emphasize the roles of the treating physician and the radiation safety officer in individualizing the precautions for each patient while allowing the referring physician to assist in preparing appropriate and adequate pre- and post-therapy actions. We tried to summarize the reported scientific papers and recommendations to provide general principle of radiation protection and some delicate issues in radiation safety after radioiodine therapy for the thyroid disease, to lower radiation exposure from patients to public and medical.
Abstract
Radioactive iodine (131I) therapy is a well established treatment modality for patient with hyperthyroidism and differentiated thyroid cancer after total thyroidectomy. Patients may sometimes need to be hospitalized to reduce radiation exposure of other people and relatives from radioactive patients receiving 131I therapy. This review was prepared to present suggestions and recommendations to health providers with reasoned instructions on radiation safety for patients, their families, caregivers, and the public after 131I therapy. The recommendations should help to ensure compliance and reduce the potential for harmful radiation exposure to others, and also to recognize that required actions may differ when attaining compliance with existing local regulations of other jurisdictions. Most of reported suggestions and recommendations are based on data derived from relevant measurements of radiation exposure, 131I clearance and excretion, and reports of the impact of precautions in limiting radiation exposure. We have quoted many descriptions from American Thyroid Association Guidelines in this review, which was published recently and emphasize the roles of the treating physician and the radiation safety officer in individualizing the precautions for each patient while allowing the referring physician to assist in preparing appropriate and adequate pre- and post-therapy actions. We tried to summarize the reported scientific papers and recommendations to provide general principle of radiation protection and some delicate issues in radiation safety after radioiodine therapy for the thyroid disease, to lower radiation exposure from patients to public and medical.
참고문헌 (20)
- Meier DA, "Procedure guideline for therapy of thyroid disease with (131)iodine", J Nucl Med, 43(6), pp.856~861 (2002)
- Luster M, "Guidelines for radioiodine therapy of differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 35(10), pp.1941~1959 (2008)
- Franzius C, "Procedure guideline for radioiodine therapy and 131Iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer", Nuklearmedizin, 46(5), pp.224~231 (2007)
- Sisson JC, "Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association", Thyroid, 21(4), pp.335~346 (2011)
- Barrington SF, "Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid", Eur J Nucl Med, 23(2), pp.123~130 (1996)
- Culver CM, "Radiation safety considerations for post-iodine-131 hyperthyroid therapy", J Nucl Med, 32(1), pp.169~173 (1991)
- O'Doherty MJ, "Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis", Nucl Med Commun, 14(3), pp.160~168 (1993)
- "United States Nuclear Regulatory Commission Office of Federal and State Material and Environmental Management Programs 2009", 20555-0001. NRC Information Notice 2003-22, Supplement 2009, ~ (2009)
- "교육과학기술부령제 24호. 방사선 안전관리 등의 기술 기준에 관한 규칙", ~ (2008)
- Jacobson AP, "Contamination of the home environment by patients treated with Iodine-131: initial results", Am J Public Health, 68(3), pp.225~230 (1978)
- Harbert JC, "Radiation exposure to the family of radioactive patients", J Nucl Med, 15(10), pp.887~888 (1974)
- Berg G, "Consequences of inadvertent radioiodine treatment of Graves' disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing?", Acta Oncol, 47(1), pp.145~149 (2008)
- Zanzanico PB, "Radiation hazards in children born to mothers exposed 131-iodine, In The thyroid and pregnancy", pp.189~202 (1991), Schattauer
- Sawka AM, "A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors", Clin Endocrinol (Oxf), 69(3), pp.479~490 (2008)
- Sawka AM, "A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors", Clin Endocrinol (Oxf), 68(4), pp.610~617 (2008)
- Azizi F, "Breastfeeding and maternal and infant iodine nutrition", Clin Endocrinol (Oxf), 70(5), pp.803~809 (2009)
- Brzozowska M, "Timing and potential role of diagnostic I-123 scintigraphy in assessing radioiodine breast uptake before ablation in postpartum women with thyroid cancer: a case series", Clin Nucl Med, 31(11), pp.683~687 (2006)
- "International Commission on Radiological Protection 2004 Release of patients after therapy with unsealed radionuclides", Ann ICRP
- Dauer LT, "Tl-201 stress tests and homeland security", J Nucl Cardiol, 14(4), pp.582~588 (2007)
- Beasley CW, "Release instructions for hyperthyroid patients treated with I-131", Thyroid, 21(10), pp.1163~1165 (2011)